This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    119-011
Previous Study | Return to List | Next Study

Candesartan Cilexetil/Amlodipine Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT02068495
First received: February 19, 2014
Last updated: NA
Last verified: February 2014
History: No changes posted
  Purpose
This study will investigate the safety and efficacy of long-term use of candesartan cilexetil/amlodipine combination tablets (Unisia Combination Tablets) LD, HD in patients with hypertension in the normal clinical setting.

Condition Intervention
Hypertension Drug: Candesartan cilexetil/amlodipine

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Unisia Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Frequency of adverse events and adverse drug reactions [ Time Frame: 12 months from the baseline ]
    Frequency, severity, and time to onset of adverse events and adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions..


Secondary Outcome Measures:
  • Changes in blood pressure, achievement rate of the target blood pressure levels [ Time Frame: 12 months from baseline ]
    Calculation of summary statistics for actual measurement values and the change from baseline in systolic and diastolic blood pressure.


Enrollment: 3409
Study Start Date: June 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Candesartan cilexetil/amlodipine
8 mg/2.5 mg or 8 mg/5 mg, orally, once daily
Drug: Candesartan cilexetil/amlodipine
Candesartan cilexetil/amlodipine tablets
Other Name: Unisia Combination Tablets

Detailed Description:

This special drug use surveillance was designed to investigate the safety and efficacy of long-term use of candesartan cilexetil/amlodipine combination tablets (Unisia Combination Tablets) in patients with hypertension in the routine clinical setting.

The usual adult dosage is one tablet (8 mg/2.5 mg or 8 mg/5 mg as candesartan cilexetil/amlodipine) administered orally once daily.

  Eligibility

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hypertension
Criteria

Inclusion Criteria:

  • Patients with hypertension

Exclusion Criteria:

  • Patients in whom Unisia is contraindicated [Contraindications]

    1. Patients with a history of hypersensitivity to the ingredients of Unisia or any other dihydropyridine formulations
    2. Women who are pregnant or of child-bearing potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02068495

Sponsors and Collaborators
Takeda
Investigators
Study Chair: Postmarketing Group Manager Takeda
  More Information

Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT02068495     History of Changes
Other Study ID Numbers: 119-011
JapicCTI-132390 ( Registry Identifier: JapicCTI )
Study First Received: February 19, 2014
Last Updated: February 19, 2014

Keywords provided by Takeda:
Drug therapy

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Candesartan
Candesartan cilexetil
Amlodipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists

ClinicalTrials.gov processed this record on August 18, 2017